The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to ...

Ascletis Pharma’s acne pill has scored a phase 3 win, leading the Chinese biotech to claim the Sagimet Biosciences-sourced ...

Chin acne is the worst, and it usually involves big, painful pimples that continue to pop up again and again. These types of ...

Experts say these 7 foods can cause inflammation, hormone spikes, and breakouts in adults with acne-prone skin.

In that same study, another group used 0.1% adapalene in cream associated with spironolactone with similar results. Other authors have shown improvement in inflammatory acne in adolescents and adults ...

“Overall, the evidence of using toothpaste on acne is minimal and anecdotal,” Jacqueline Watchmaker, MD, a board-certified dermatologist based in Scottsdale, Arizona, told Health ...

So, it is important to understand why adult acne occurs to both heal it and take preventive measures. Before making any major skincare changes, always consult your dermatologist, who can also ...

His comments on current studies of spironolactone in HENEF are encouraging since results with ACE inhibitors and AR blockers up to date were surprisingly negative. We have investigated the efficacy of ...

Amiloride, a potassium-sparing diuretic, was noninferior to spironolactone in reducing home-measured systolic blood pressure (BP) after 12 weeks of treatment in patients with true resistant ...

You should use exfoliating toners only a couple of times a week. Most skin care products are applied evenly over the entire face, but spot treatments are applied directly to acne, hyperpigmentation ...

Amiloride is noninferior to spironolactone in lowering home systolic blood pressure over 12 weeks in patients with resistant hypertension. The finding is from the SPironolactone Versus Amiloride ...

Noninferiority trial favored amiloride as an alternative to spironolactone in lowering home systolic blood pressure (SBP) for people with resistant hypertension. Twelve weeks into the trial ...